Follows pregnant women with migraine who take erenumab
Tracks babies born to women with migraine who took erenumab during pregnancy.
Plain-language title generated from the registry record
Registry title: Aimovig Pregnancy Exposure Registry
Key facts
- Where
- Durham, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06150781, who can take part
Where in United States
- DurhamDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT06150781
- Record updated
- 4 November 2025
- Original description
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.Read full original descriptionShow less
GENESIS: AIMOVIG® Pregnancy Exposure Registry
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Inclusion: Age 18 years or older (at time of signing the informed consent); Currently pregnant; The outcome of the pregnancy must not be known; Confirmed clinical diagnosis of migraine.
Exclusion: Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded; Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody [mAb] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy.